Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 58.7% in January

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 31,500 shares, a decline of 58.7% from the December 31st total of 76,200 shares. Based on an average daily trading volume, of 787,700 shares, the short-interest ratio is presently 0.0 days.

Astellas Pharma Trading Down 0.6 %

Shares of OTCMKTS:ALPMY opened at $9.78 on Thursday. The company’s 50-day moving average price is $9.89 and its two-hundred day moving average price is $10.99. Astellas Pharma has a one year low of $9.05 and a one year high of $13.14. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.10 and a quick ratio of 0.86. The stock has a market capitalization of $17.70 billion, a PE ratio of 46.57 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $3.11 billion during the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. On average, equities analysts forecast that Astellas Pharma will post 0.61 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.